Abbisko Therapeutics Co., Ltd.

Merck KGaA only has two-late stage candidates in its pipeline but CEO Belén Garijo has told Scrip that the German company is laser-focused on adding more assets. Speaking at Merck’s annual press con

Following a couple of fairly disastrous trial failures, Merck KGaA can finally celebrate a hit. The colony stimulating factor-1 (CSF-1) inhibitor pimicotinib, originated by China-based Abbisko and lic

Any investor hoping Merck KGaA would make big changes to its biopharma R&D strategy after two late-stage failures will have been disappointed by its latest pronouncements. The German conglomerate sa

Wrapping up a challenging 2023, Chinese pharma firms increasingly ventured into the US to initiate Phase III clinical trials to support future regulatory approvals from the US Food and Drug Administra